Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?
Quinn
Martin J
MJ
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Plow
Edward F
EF
Topol
Eric J
EJ
D000208:Acute Disease; D000284:Administration, Oral; D001792:Blood Platelets / Q000187:drug effects; D023201:CD40 Ligand / Q000502:physiology; D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007249:Inflammation / Q000209:etiology; D007262:Infusions, Intravenous; D008955:Models, Cardiovascular; D017202:Myocardial Ischemia / Q000517:prevention & control; D009204:Myocardial Revascularization; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D013577:Syndrome; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D023201:CD40 Ligand